Should newly diagnosed epilepsy be treated with generics?

Nature Clinical Practice Neurology

Volumn 4, Issue 4, 2008, Pages 176-177

  Wolf, Peter ^a,b  

^a Mental Health Services CPH   (Denmark)

^b DANISH EPILEPSY CENTRE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GENERIC DRUG; LAMOTRIGINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG LEGISLATION; DRUG MARKETING; DRUG MEGADOSE; DRUG MONITORING; DRUG QUALITY; DRUG SUBSTITUTION; EPILEPSY; GOVERNMENT REGULATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRESCRIPTION; PRIORITY JOURNAL; SEIZURE; SUSTAINED RELEASE PREPARATION; TERTIARY HEALTH CARE;

DRUGS, GENERIC; EPILEPSY; HUMANS;

EID: 42049122567     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0753     Document Type: Article

References (7)

1. Bialer M (2007) Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia 48: 1825-1832
2. Brodie MJ (2005) Response to antiepileptic drug therapy: Winners and losers. Epilepsia 46(Suppl 10): S31-S32
3. Kutt H (1972) Relation of plasma levels to clinical control. In Antiepileptic Drugs, 211-218 (Eds Woodbury DM et al.) New York. Raven Press
4. Søndergaard Khinchi M et al. (2008) Lamotrigine therapeutic thresholds. Seizure [doi:10.1016/j.seizure.2007.11.023]
5. Mayer T et al. (1999) Clinical problems with generic antiepileptic drugs: Comparison of sustained-release formulations of carbamazepine. Clin Drug Invest 18: 17-26
6. Perucca E et al. (2006) Recommendations of the Italian League Against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47 (Suppl 5): S16-S20
7. Wolf P (2007) Generic antiepileptic drugs: Political campaign in Denmark. Epilepsia 48 (Suppl 7): S6-ST